An ad hoc committee under the National Academies of Sciences, Engineering, and Medicine announced a study that analyzed the lessons derived from the recent pandemic and the mpox multi-country outbreak.
The Future State of Smallpox Medical Countermeasures report argues that the United States and the global community should prepare for smallpox to make an unfortunate return. 
According to the report, smallpox could return through an accidental leak or even an intentional act.

Recently, a clinical trial enrollment was stopped ahead of schedule because of safety concerns. The trial's early findings indicated that the risk of severe lower respiratory tract disease in infants caused by the respiratory syncytial virus (RSV) was lower with the maternal vaccine candidate than with the placebo.
However, the risk of preterm birth was found to be higher with the candidate vaccine.

After being designated measles-free for two decades, the United States risks losing its status due to recent measles outbreaks.
Over the past fifteen months, 338 cases of measles have been reported in the U.S. Among these cases, 96% were associated with measles virus importation.
Among the 326 import-associated measles cases, 61% occurred among U.S. residents who were eligible for vaccination but were unvaccinated or whose vaccination status was unknown.
Furthermore, in 2024 alone, seven measles outbreaks (3+ cases) have been reported in the U.S.

The Department of Health (DOH) in the Republic of the Philippines has taken action to address the Pertussis outbreak.
Data as of March 30, 2024, indicates that there have been 1,112 Pertussis (whooping cough) cases since the start of 2024, which is almost 34 times higher than during the same period in 2023.
The majority of these cases were found in unvaccinated children under the age of five.
On April 11, 2024, the DOH reassured the public that outbreak response immunization was underway—however, the national government's inventory is in short supply.

In the early stages of the recent pandemic, clinical studies reported differing levels of effectiveness for COVID-19 vaccines.
One reason for this was that people's immune composition was continuously changing due to new SARS-CoV-2 variants, booster doses, and updated vaccine types.
However, one missing data component was needed to understand these innovative vaccines' effectiveness fully.
Recently, real-world evidence was published that supports the continued use of protein-based COVID-19 vaccines.

While the international community has focused on the extensive mpox outbreak in the Democratic Republic of the Congo, this sexually transmitted disease has resurfaced in the United States.
According to the U.S. Centers for Disease Control and Prevention (CDC), as of the week ending March 30, 2024 (Week #13), there were 664 mpox cases in the U.S.
New York (142), California (67), and Texas (43) are the leading states reporting mpox cases in 2024.
This data compares with just 307 reported in the same period in 2023.

The Pan American Health Organization (PAHO) recently joined the U.S. CDC in issuing dengue outbreak warnings for the Region of the Americas.
As of March 26, 2024, over 3.5 million cases and more than 1,000 deaths have been reported in the Americas.
"This is cause for concern, as it represents three times more cases than those reported for the same period in 2023, a record year with more than 4.5 million cases reported in the region," PAHO Director Jarbas Barbosa said during a recent press briefing.

Throughout the last eighteen months, the most accessible healthcare provider on 'Main Street' took the leadership position in administering updated COVID-19 vaccines.
Thanks to the U.S. Federal Retail Pharmacy Program, pharmacists scaled up their vaccination capabilities to deliver 40.5 million COVID-19 vaccinations.
Approximately 90% of U.S. residents live within 5 miles of a community pharmacy that delivers walk-up and appointment-based vaccination services.

As the Chikungunya virus (CHIKV) continues to cause outbreaks in 2024, many people ask where this disease is prevalent. This mosquito-transmitted disease generally impacts people in the tropics and sub-tropics.
According to the European Centre for Disease Prevention and Control (ECDC), approximately 70,000 CHIKV cases and 15 deaths have been reported worldwide. 
The likelihood of local transmission events of Chikungunya in mainland EU/EEA is moderate, as no cases were reported in 2023.

According to a recent Agence France Presse report, France's doctors' union claims that 27 million appointments are missed annually. To eliminate this waste of resources, the government aims to reduce this number through various measures, including launching a financial penalty.
France plans to impose a €5 ($5.41) penalty for individuals who miss a doctor's appointment.
From a controlling perspective, doctors in France would decide whether the reason for not attending a scheduled appointment is satisfactory to avoid the financial penalty.